文献速递泌尿男性生殖肿瘤

阿帕他胺联合阿比特龙和泼尼松对比安慰剂联合阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌(ACIS):随机、安慰剂对照、双盲、多国3期研究

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
PubMed 文献 · Lancet Oncol · 2021-09-30

ACIS研究纳入982例未接受化疗的mCRPC患者,随机接受阿帕他胺+阿比特龙+泼尼松或安慰剂+阿比特龙+泼尼松。最终分析总生存未见显著获益,联合组高血压和严重不良事件发生率略高。

要点

  • 联合组3-4级高血压发生率17%,高于对照组的10%。
  • 总生存最终分析未显示显著差异。

核心结论

  • 阿帕他胺联合阿比特龙和泼尼松较阿比特龙和泼尼松显著延长mCRPC患者的影像学无进展生存期。
  • 联合治疗未显著改善总生存,需进一步识别最可能获益的亚组。

研究设计与样本

  • ACIS为随机、安慰剂对照、双盲、多国3期研究,在17个国家167家医院开展。
  • 纳入982例未接受化疗的mCRPC男性患者,1:1随机分配至阿帕他胺+阿比特龙+泼尼松组(492例)或安慰剂+阿比特龙+泼尼松组(490例)。
  • 主要终点为意向治疗人群的影像学无进展生存期。

主要发现

  • 最常见的3-4级治疗中出现的不良事件为高血压,联合组82例(17%),对照组49例(10%)。
  • 严重治疗中出现的不良事件发生率联合组40%(195例),对照组37%(181例)。

关键数值与推荐

  • 3-4级高血压发生率联合组17%(82/490),对照组10%(49/489)。

临床怎么用

  • 对于未接受化疗且适合强化治疗的mCRPC患者,可考虑阿帕他胺联合阿比特龙和泼尼松方案。
  • 联合治疗需密切监测高血压等不良事件。
  • 总生存未显著改善,联合方案的选择应结合患者个体情况。

局限性

  • 最终分析未显示总生存显著获益,联合治疗的生存优势尚不明确。
  • 需进一步研究以识别最可能从联合治疗中获益的亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The majority of patients with metastatic castration-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated intratumoural androgens; however, the current standard of care is therapy that targets a single androgen signalling mechanism. We aimed to investigate the combination treatment using apalutamide plus abiraterone acetate, each of which suppresses the androgen signalling axis in a different way, versus standard care in mCRPC. METHODS: ACIS was a randomised, placebo-controlled, double-blind, phase 3 study done at 167 hospitals in 17 countries in the USA, Canada, Mexico, Europe, the Asia-Pacific region, Africa, and South America. We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors and were receiving ongoing androgen deprivation therapy, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a Brief Pain Inventory-Short Form question 3 (ie, worst pain in the past 24 h) score of 3 or lower. Patients were randomly assigned (1:1) via a centralised interactive web response system with a permuted block randomisation scheme (block size 4) to oral apalutamide 240 mg once daily plus oral abiraterone acetate 1000 mg once daily and oral prednisone 5 mg twice daily (apalutamide plus abiraterone-prednisone group) or placebo plus abiraterone acetate and prednisone (abiraterone-prednisone group), in 28-day treatment cycles. Randomisation was stratified by presence or absence of visceral metastases, ECOG performance status, and geographical region. Patients, the investigators, study team, and the sponsor were masked to group assignments. An independent data-monitoring committee continually monitored data to ensure ongoing patient safety, and reviewed efficacy data. The primary endpoint was radiographic progression-free survival assessed in the intention-to-treat population. Safety was reported for all patients who received at least one dose of study drug. This study is completed and no longer recruiting and is registered with ClinicalTrials.gov, number NCT02257736. FINDINGS: 982 men were enrolled and randomly assigned from Dec 10, 2014 to Aug 30, 2016 (492 to apalutamide plus abiraterone-prednisone; 490 to abiraterone-prednisone). At the primary analysis (median follow-up 25·7 months [IQR 23·0-28·9]), median radiographic progression-free survival was 22·6 months (95% CI 19·4-27·4) in the apalutamide plus abiraterone-prednisone group versus 16·6 months (13·9-19·3) in the abiraterone-prednisone group (hazard ratio [HR] 0·69, 95% CI 0·58-0·83; p<0·0001). At the updated analysis (final analysis for overall survival; median follow-up 54·8 months [IQR 51·5-58·4]), median radiographic progression-free survival was 24·0 months (95% CI 19·7-27·5) versus 16·6 months (13·9-19·3; HR 0·70, 95% CI 0·60-0·83; p<0·0001). The most common grade 3-4 treatment-emergent adverse event was hypertension (82 [17%] of 490 patients receiving apalutamide plus abiraterone-prednisone and 49 [10%] of 489 receiving abiraterone-prednisone). Serious treatment-emergent adverse events occurred in 195 (40%) patients receiving apalutamide plus abiraterone-prednisone and 181 (37%) patients receiving abiraterone-prednisone. Drug-related treatment-emergent adverse events with fatal outcomes occurred in three (1%) patients in the apalutamide plus abiraterone-prednisone group (2 pulmonary embolism, 1 cardiac failure) and five (1%) patients in the abiraterone-prednisone group (1 cardiac failure and 1 cardiac arrest, 1 mesenteric arterial occlusion, 1 seizure, and 1 sudden death). INTERPRETATION: Despite the use of an active and established therapy as the comparator, apalutamide plus abiraterone-prednisone improved radiographic progression-free survival. Additional studies to identify subgroups of patients who might benefit the most from combination therapy are needed to further refine the treatment of mCRPC. FUNDING: Janssen Research & Development.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Saad F, Efstathiou E, Attard G, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021. PMID: 34600602. doi:10.1016/S1470-2045(21)00402-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。